Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer

被引:19
作者
Arcangeli, G
Saracino, B
Arcangeli, G
Angelini, F
Marchetti, P
Danesi, DT
机构
[1] Regina Elena Inst Canc Res, Div Radiat Oncol, I-00144 Rome, Italy
[2] Santa Maria Goretti Hosp, Div Med Oncol, Latina, Italy
[3] Univ Aquila, Div Med Oncol, I-67100 Laquila, Italy
[4] ENEA Casaccia, Rome, Italy
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 54卷 / 04期
关键词
gastric cancer; combined radiotherapy and chemotherapy; hyperfractionation;
D O I
10.1016/S0360-3016(02)03026-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: The 5-year survival of patients with completely resected node-positive gastric cancer ranges from 15% to 25%. We explored the feasibility of a chemoradiation regime consisting of concomitant hyperfractionated radiotherapy and 5-fluorouracil protracted venous infusion (5-FU PVI). Materials and Methods: Forty patients received a total or partial gastrectomy operation and D2 nodal resection for Stage III gastric cancer; they were then irradiated by linac with 6-15-MV photons. The target included the gastric bed, the anastomosis, stumps, and regional nodes. A total dose of 55 Gy was given in 50 fractions using 1.1 Gy b.i.d. All patients received a concomitant 200 mg/m(2)/day 5-FU PVI. Patients were examined during the follow-up period as programmed. Toxicity was recorded according to RTOG criteria. Results: After a median follow-up of 75.6 months (range: 22-136 months), 24 (60%) patients had died, and 16 (40%) were alive and free of disease. The 5-year actuarial incidence of relapse was 39%, 22%, and 2% for distant metastases, out-field peritoneal seeding, and in-field local regional recurrences, respectively. The 5-year actuarial cause-specific survival was 43 %. Three patients survived more than 11 years. Acute greater than or equal to Grade 3 toxicity consisted of hematologic (22.5%) and gastrointestinal toxicity (nausea and vomiting 22.5%, diarrhea 2.8%, and abdominal pain 2.6%). No late toxicity was observed. Conclusion: This regime of concomitant 5-FU PVI and hyperfractionated radiotherapy was well tolerated and resulted in successful locoregional control and satisfactory survival. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:1069 / 1075
页数:7
相关论文
共 30 条
[1]
[Anonymous], CANC OS STOMACH
[2]
A PILOT-STUDY OF CONCOMITANT PROTRACTED VENOUS INFUSION 5-FLUOROURACIL AND HYPERFRACTIONATED RADIOTHERAPY IN RECTAL TUMORS [J].
ARCANGELI, G ;
ANGELINI, F ;
ARCANGELI, G ;
TERSIGNI, R ;
DAPRILE, M ;
MICHELI, A ;
VELTRI, E ;
AMBROGI, C ;
ALESSANDRONI, L ;
GIOVINAZZO, G ;
DANGELO, L .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (05) :369-375
[3]
RANDOMIZED COMPARISON OF MORBIDITY AFTER D1 AND D2 DISSECTION FOR GASTRIC-CANCER IN 996 DUTCH PATIENTS [J].
BONENKAMP, JJ ;
SONGUN, I ;
HERMANS, J ;
SASAKO, M ;
WELVAART, K ;
PLUKKER, JTM ;
VANELK, P ;
OBERTOP, H ;
GOUMA, DJ ;
TAAT, CW ;
VANLANSCHOT, J ;
MEYER, S ;
DEGRAAF, PW ;
VONMEYENFELDT, MF ;
TILANUS, H ;
VANDEVELDE, CJH .
LANCET, 1995, 345 (8952) :745-748
[4]
Extended lymph-node dissection for gastric cancer [J].
Bonenkamp, JJ ;
Hermans, J ;
Sasako, M ;
van de Velde, CJH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12) :908-914
[5]
PHARMACOLOGIC REQUIREMENTS FOR OBTAINING SENSITIZATION OF HUMAN-TUMOR CELLS-INVITRO TO COMBINED 5-FLUOROURACIL OR FTORAFUR AND X-RAYS [J].
BYFIELD, JE ;
CALABROJONES, P ;
KLISAK, I ;
KULHANIAN, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (11) :1923-1933
[6]
RADIOTHERAPY OF GASTRIC-CANCER WITH A 3 FIELD COMBINATION - FEASIBILITY, TOLERANCE, AND SURVIVAL [J].
CAUDRY, M ;
ESCARMANT, P ;
MAIRE, JP ;
DEMEAUX, H ;
GUICHARD, F ;
AZALOUX, H .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (12) :1821-1827
[7]
TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[8]
CUSCHIERI A, 1999, BRIT J CANCER, V79, P1422
[9]
RANDOMIZED COMPARISON OF R1 AND R2-GASTRECTOMY FOR GASTRIC-CARCINOMA [J].
DENT, DM ;
MADDEN, MV ;
PRICE, SK .
BRITISH JOURNAL OF SURGERY, 1988, 75 (02) :110-112
[10]
EARL CC, 1998, J CLIN ONCOL, V175, pA263